<DOC>
	<DOCNO>NCT03056118</DOCNO>
	<brief_summary>Investigators try assess safety 6-months 12-months maintenance dual antiplatelet therapy ( DAPT , aspirin + clopidogrel ) patient undergo percutaneous coronary intervention use Zotarolimus-eluting , Resolute Integrity™ stent ( Medtronic Vascular Inc , Santa Rosa , CA ) BioMatrix™ stent ( Biosensors . Singapore ) .</brief_summary>
	<brief_title>Optimal Duration Clopidogrel Second-Generation Drug-Eluting Stents</brief_title>
	<detailed_description>Dual antiplatelet therapy ( DAPT ) proven effective treatment reduce thrombotic complication drug elute stent ( DES ) implantation . Although optimal duration antiplatelet therapy still investigation , late stent thrombosis ( ST ) DES push recommendation duration clopidogrel therapy one year , patient without risk bleed . However , recent controversy regard risk stent thrombosis patient receive DES bring issue appropriate duration antiplatelet therapy percutaneous coronary intervention , recent study report use extend DAPT period longer 12 month patient receive DES significantly effective aspirin monotherapy reduce rate myocardial infarction ( MI ) death cardiac cause . Zotarolimus-eluting stent ( Resolute Integrity™ ) biolimus-eluting stent biodegradable polymer system ( BioMatrix™ ) share several similarity . Both stent flexible thin strut stent elute sirolimus-analogue drug target mammalian target rapamycin . The advantage Resolute Integrity™ stent strut quite thin coat highly biocompatible polymer BioMatrix™ stent abluminal drug coating system biodegradable polymer might provide clinical study show stent quite safe well efficacious . Moreover , recent report show continuation clopidogrel 3 month implantation Endeavor stent seem safe low-to-moderate coronary artery risk group . Based clinical evidence , duration DAPT continuation 12 month less implantation Resolute Integrity™ BioMatrix™ stent , 'the second generation DES ' , would safe , however , data available . Therefore , purpose study assess safety 6-months 12-months maintenance DAPT patient undergo percutaneous coronary intervention ( PCI ) use Resolute Integrity™ BioMatrix™ stent .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Subject must least 20 year age . 2 . Subject must evidence myocardial ischemia ( e.g . stable angina , nonST elevation acute coronary syndrome , silent ischemia , positive functional study reversible change electrocardiogram ( ECG ) consistent ischemia ) . 3 . Subject able verbally confirm understandings risk , benefit treatment alternative receive Resolute Integrity BioMatrix stent he/she his/her legally authorize representative provide write informed consent prior study related procedure . 1 . Acute ST elevation myocardial infarction 2 . The patient know hypersensitivity contraindication follow medication : heparin , aspirin , clopidogrel , zotarolimus , biolimus , contrast medium 3 . Clinical condition require systemic immune suppression 2 week anticancer therapy 4 . Prior history follow presentation : Thromboembolic disease , Stent thrombosis 5 . Pregnant woman woman childbearing potential , unless recent pregnancy test negative , possibly plan become pregnant time enrollment study . 6 . History bleed diathesis know coagulopathy ( include heparininduced thrombocytopenia ) , refuse blood transfusion . 7 . Gastrointestinal genitourinary bleeding within prior 3 month , major surgery within 2 month . 8 . Current know current platelet count &lt; 100,000 cells/mm3 Hgb &lt; 10 g/dL . 9 . Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance ( per site investigator 's medical judgment 10 . Patients leave ventricular ejection fraction &lt; 35 % 11 . Patients cardiogenic shock 12 . Creatinine level &gt; 2.4mg/dL 13 . Severe hepatic dysfunction ( aspartate aminotransferase and/or alanine aminotransferase ≥ 3 time upper normal reference value )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>OPTIMA-C</keyword>
</DOC>